Firethorn Wealth Partners LLC Makes New Investment in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Firethorn Wealth Partners LLC acquired a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 26,013 shares of the biotechnology company’s stock, valued at approximately $52,000.

A number of other hedge funds have also made changes to their positions in HRTX. nVerses Capital LLC acquired a new position in Heron Therapeutics in the second quarter valued at approximately $27,000. Headlands Technologies LLC acquired a new position in shares of Heron Therapeutics in the 1st quarter valued at $30,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Heron Therapeutics in the 1st quarter valued at $32,000. HB Wealth Management LLC purchased a new position in shares of Heron Therapeutics in the 2nd quarter valued at $35,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in Heron Therapeutics during the 2nd quarter worth $41,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Trading Up 3.9 %

Shares of NASDAQ HRTX opened at $1.87 on Thursday. The stock has a market cap of $281.72 million, a P/E ratio of -3.07 and a beta of 1.80. Heron Therapeutics, Inc. has a twelve month low of $0.50 and a twelve month high of $3.93. The stock has a 50 day moving average of $1.93 and a two-hundred day moving average of $2.66.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The firm had revenue of $36.02 million for the quarter, compared to analyst estimates of $35.35 million. During the same quarter last year, the firm earned ($0.35) earnings per share. As a group, research analysts predict that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a report on Wednesday, September 25th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.